American Society of Hirudotherapy

Hementin-Like Protein (HLP-1)

Fibrinogenolytic / anti-platelet protein homologous to hementin — disrupts platelet aggregation.

Preclinical / mechanisticLast updated: 2026-05-26 · Reviewed by ASH Editorial Board
Molecular weight of Hementin-Like Protein (HLP-1) compared with other characterized leech-derived compoundsHementin-Like Protein (HLP-1)80 kDaHementerin80 kDaHementin80 kDaLeech Collagenase70 kDaHaemadipsa yanyuanensis Progr…70 kDaLeech Apyrase67 kDaCalin65 kDaHyaluronidase60 kDaAntithrombin III binding prot…58 kDaCollagenolytic Fibrinolysin55 kDaLeech Thrombospondin-Like Pro…50 kDaLHyal (Leech Hyaluronidase)50 kDa
Molecular weight (kilodaltons) of Hementin-Like Protein (HLP-1) (highlighted) alongside other characterized leech salivary compounds. Smaller proteins/peptides generally diffuse and act faster.

Mechanistic Evidence Box

Preclinical / mechanistic
Page type
Compound profile
Evidence type
Fibrinogenolytic / anti-platelet protein homologous to hementin — disrupts platelet aggregation.
Evidence level
In vitro
Drug vs leech
Purified natural compound
Safety domains
Bleeding

Clinical translation limit

HLP-1 is documented mechanistically only; no human evidence. Homology to hementin does NOT establish clinical efficacy, and no FDA-approved derivative exists.

Molecular Profile

Category
Antiplatelet
Evidence tier
Preclinical
Molecular weight
80,000 Da
Source species
Haementeria-related species
Discovered
2006
Hementin-Like Protein (HLP-1) molecular structure

Biological Targets

  • fibrinogen
  • platelet aggregation

External Resources

    Related Antiplatelet Compounds

    This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.